Online citations, reference lists, and bibliographies.

The Human Gut-Liver-Axis In Health And Disease

A. Krag, T. Hansen
Published 2019 ·

Cite This
Download PDF
Analyze on Scholarcy
Share
This paper references
10.3109/00365521.2012.661759
Incidence, etiology and mortality of cirrhosis: a population-based cohort study
A. D. Fialla (2012)
The effect of acute
WJ deJong
10.1002/hep.27678
Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases–U.S. Food and Drug Administration Joint Workshop
A. Sanyal (2015)
Evolution of non - invasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C
J Vergniol (2014)
10.1152/ajpgi.00447.2014
Novel insights into the function and dynamics of extracellular matrix in liver fibrosis.
M. Karsdal (2015)
10.1016/j.jhep.2015.04.006
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis.
Asociacion Latinoamericana para el Estudio del Higado (2015)
10.1016/S0140-6736(14)61933-4
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
B. A. Neuschwander-Tetri (2015)
10.1016/J.DRUGALCDEP.2006.06.008
Alcohol treatment utilization: findings from the National Epidemiologic Survey on Alcohol and Related Conditions.
Emily Cohen (2007)
10.1038/nrgastro.2015.35
Alcoholic liver disease: mechanisms of injury and targeted treatment
A. Louvet (2015)
10.1016/j.alcohol.2014.09.033
The effect of acute alcohol intoxication on gut wall integrity in healthy male volunteers; a randomized controlled trial.
Wilfried de Jong (2015)
10.1111/acer.12780
The Utility of Commonly Used Laboratory Tests to Screen for Excessive Alcohol Use in Clinical Practice.
Gina Gough (2015)
10.1111/liv.13260
Transient elastography for the diagnosis of liver fibrosis: a systematic review of economic evaluations
S. van Katwyk (2017)
10.1136/gutjnl-2015-309265
Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study
R. Kwok (2015)
10.1152/ajpgi.00380.2011
Colonic microbiome is altered in alcoholism.
E. Mutlu (2012)
10.1002/hep.23500
Clinical course of alcoholic liver cirrhosis: A Danish population‐based cohort study
P. Jepsen (2010)
10.1159/000443361
The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin
F. Ponziani (2016)
10.1007/s12072-016-9772-z
Non-invasive diagnosis of hepatic steatosis
C. Stern (2016)
10.1136/gutjnl-2016-312729
Gut microbiome and liver diseases
H. Tilg (2016)
10.1053/j.gastro.2015.09.040
Transient and 2-Dimensional Shear-Wave Elastography Provide Comparable Assessment of Alcoholic Liver Fibrosis and Cirrhosis.
M. Thiele (2016)
10.1038/ajg.2015.191
Causes of Death in People with Liver Cirrhosis in England Compared with the General Population: A Population-Based Cohort Study
S. Ratib (2015)
10.1016/j.jhep.2013.03.007
Global burden of alcoholic liver diseases.
J. Rehm (2013)
10.1111/apt.12820
Review article: the efficacy of biomarkers in chronic fibroproliferative diseases – early diagnosis and prognosis, with liver fibrosis as an exemplar
M. A. Karsdal (2014)
10.1053/j.gastro.2014.11.023
Dietary saturated lipids in alcoholic liver disease: new microbiota-targeting bullets?
Herbert Tilg (2015)
10.1111/hepr.12131
Effect of abstinence from alcohol on survival of patients with alcoholic cirrhosis: A systematic review and meta‐analysis
Y. Xie (2014)
10.1002/cld.172
Histopathology of alcoholic liver disease
N. Theise (2013)
10.1016/j.jhep.2016.06.018
Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide.
E. Stein (2016)
10.1093/ALCALC/35.5.478
The long-term cost-effectiveness of improving alcohol abstinence with adjuvant acamprosate.
A. Palmer (2000)
10.1053/j.gastro.2014.10.042
Gut-liver axis in alcoholic liver disease.
G. Szabo (2015)
10.1002/hep.27069
Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C
J. Vergniol (2014)
10.1111/add.13799
Alcohol dependence and risk of somatic diseases and mortality: a cohort study in 19 002 men and women attending alcohol treatment
C. Holst (2017)
10.1111/add.13757
The relationship between different dimensions of alcohol use and the burden of disease—an update
J. Rehm (2017)
10.1002/hep.27981
Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study
Edith M. Koehler (2016)
10.1111/acer.12887
Clinical impact of alcohol-related cirrhosis in the next decade: estimates based on current epidemiological trends in the United States.
John Guirguis (2015)
10.1371/journal.pone.0096864
Acute Binge Drinking Increases Serum Endotoxin and Bacterial DNA Levels in Healthy Individuals
S. Bala (2014)
10.1053/J.GASTRO.2007.05.024
Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.
C. Ripoll (2007)
10.1136/gutjnl-2015-310585
Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease
M. Llopis (2015)
10.1016/S0140-6736(13)62152-2
Liver disease in the UK: a Lancet Commission
R. Williams (2013)
10.3748/wjg.v23.i17.3163
Cost-effectiveness of enhanced liver fibrosis test to assess liver fibrosis in chronic hepatitis C virus and alcoholic liver disease patients
M. Soto (2017)
10.1136/bcr-2013-201618
Cirrhosis improvement to alcoholic liver fibrosis after passive abstinence
H. Takahashi (2014)
10.1186/s12889-015-1860-9
Evaluation of work-based screening for early signs of alcohol-related liver disease in hazardous and harmful drinkers: the PrevAIL study
Penny A Cook (2015)
10.1016/j.jhep.2015.05.022
Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension.
R. de Franchis (2015)
10.1016/j.ultrasmedbio.2017.08.1487
Transient Elastography for Diagnosis of Stages of Hepatic Fibrosis and Cirrhosis in People with Alcoholic Liver Disease
C. Pavlov (2017)
10.1002/HEP.510270601
Hepatic steatosis: Innocent bystander or guilty party?
C. Day (1998)
10.1016/J.ALCOHOL.2004.07.008
Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis.
C. Lieber (2004)
10.1111/j.1465-3362.2009.00153.x
Alcohol as a risk factor for liver cirrhosis: a systematic review and meta-analysis.
J. Rehm (2010)
10.1111/j.1365-2036.2012.05091.x
Cirrhosis and mortality risks of biopsy‐verified alcoholic pure steatosis and steatohepatitis: a nationwide registry‐based study
T. Deleuran (2012)
10.1016/S0140-6736(08)60383-9
Liver cirrhosis
D. Schuppan (2008)
10.1016/j.jhep.2016.08.011
The genetics of alcohol dependence and alcohol-related liver disease.
F. Stickel (2017)
10.1016/j.jhep.2010.07.016
Incidence and mortality of alcoholic hepatitis in Denmark 1999-2008: a nationwide population based cohort study.
T. Sandahl (2011)
10.1159/000371678
Gut Microbiota, Cirrhosis, and Alcohol Regulate Bile Acid Metabolism in the Gut
J. Ridlon (2015)
10.1016/j.jhep.2015.11.006
Alcohol and liver disease in Europe--Simple measures have the potential to prevent tens of thousands of premature deaths.
N. Sheron (2016)
10.1038/srep45176
Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia
L. Xue (2017)
10.1016/j.jhep.2017.05.007
Targeting the gut-liver axis in liver disease.
R. Wiest (2017)
10.1152/ajpgi.00245.2016
Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota.
S. Bluemel (2016)
10.1111/J.1360-0443.2006.01310.X
Rates and predictors of relapse after natural and treated remission from alcohol use disorders.
R. Moos (2006)
10.1111/j.1478-3231.2012.02774.x
Beneficial effects of candesartan, an angiotensin‐blocking agent, on compensated alcoholic liver fibrosis ‐ A randomized open‐label controlled study
M. Y. Kim (2012)
10.1016/S0140-6736(15)00803-X
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
M. Armstrong (2016)
10.1136/bmj.i124
Decompensated alcohol related liver disease: acute management
S. McPherson (2016)
10.1038/nrgastro.2016.86
Critical comparison of elastography methods to assess chronic liver disease
M. Friedrich-Rust (2016)
10.1038/nrgastro.2009.149
The clinical use of HVPG measurements in chronic liver disease
J. Bosch (2009)
10.1034/j.1600-0676.2003.01804.x
Five‐year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence
F. Pessione (2003)
microbiome and liver diseases
CS Lieber
10.1111/j.1530-0277.2010.01374.x
Effect of detoxification on liver stiffness assessed by Fibroscan® in alcoholic patients.
E. Gelsi (2011)
10.1136/bmj.i1860
Effect of policy, economics, and the changing alcohol marketplace on alcohol related deaths in England and Wales
N. Sheron (2016)
10.1136/gut.41.6.845
Drinking habits as cofactors of risk for alcohol induced liver damage
S. Bellentani (1997)
10.1001/jama.2014.3628
Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis.
D. Jonas (2014)
10.1038/nrgastro.2015.94
Inflammasome activation and function in liver disease
G. Szabo (2015)
10.1016/j.jhep.2016.11.011
Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease.
C. Lackner (2017)
10.1016/j.jhep.2014.12.005
Alcohol drinking pattern and risk of alcoholic liver cirrhosis: a prospective cohort study.
G. Askgaard (2015)
10.1002/hep.20701
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
D. Kleiner (2005)
10.1111/apt.12721
Competing risks and prognostic stages of cirrhosis: a 25‐year inception cohort study of 494 patients
G. D'Amico (2014)
10.1136/bmj.c1240
Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies
C. Hart (2010)
10.1172/JCI90562
Intestinal fungi contribute to development of alcoholic liver disease
An-Ming Yang (2017)
10.1371/journal.pone.0060042
Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy
J. Bajaj (2013)



Semantic Scholar Logo Some data provided by SemanticScholar